Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?
Genenta’s Oct. 24 announcement ignited optimism. According to the official press release, Anemocyte will incorporate Genenta’s clinically validated LVV plasmid DNA platform into its production pipeline investing.com. “By making our clinically validated LVV plasmid DNA technology platform available to Anemocyte and its clients, we are contributing to the reliable and scalable development of advanced therapy programs across the industry,” said CEO Pierluigi Paracchi investing.com. Anemocyte’s CEO Marco Ferrari added that the deal ensures customers have access to “a robust, well-established platform” for cutting-edge cell therapies investing.com. In effect, the partnership helps Genenta and its clients secure high-quality plasmid DNA from R&D through GMP stages, a critical bottleneck for gene therapy developers stocktitan.net investing.com.
